Silverarc Capital Management’s Gossamer Bio GOSS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
– Sell
-26,697
Closed -$6.62M – 78
2025
Q4
$6.62M Sell
26,697
-33,042
-55% -$7.54M 0.92% 30
2025
Q3
$12.6M Sell
59,739
-4,596
-7% -$810K 1.69% 18
2025
Q2
$6.33M Sell
64,335
-14,674
-19% -$1.28M 1.17% 24
2025
Q1
$6.95M Buy
79,009
+1,861
+2% +$172K 1.42% 22
2024
Q4
$5.58M Buy
77,148
+6,581
+9% +$451K 1.22% 28
2024
Q3
$5.57M Buy
70,567
+1,817
+3% +$140K 1.25% 27
2024
Q2
$4.95M Sell
68,750
-7,878
-10% -$471K 1.17% 29
2024
Q1
$7.23M Hold
76,628
– – 2.01% 17
2023
Q4
$5.59M Hold
76,628
– – 1.67% 24
2023
Q3
$5.11M Buy
+76,628
New +$7.06M 1.55% 28
2023
Q1
– Sell
-1,250
Closed -$217K – 89
2022
Q4
$217K Buy
+1,250
New +$823K 0.06% 85

Other funds holding GOSS

Silverarc Capital Management's GOSS Position: Q1 2026 in Review

Silverarc Capital Management sold out of Gossamer Bio (GOSS) in Q1 2026, closing a stake of 26,697 shares — an estimated $6.62M sold.

Silverarc Capital Management first reported a position in GOSS in Q4 2022 and held it in 11 quarters. The position peaked at $12.6M in Q3 2025. 181 funds tracked by Wall St. Rank hold GOSS as of Q1 2026.

  • Silverarc Capital Management reported no remaining Gossamer Bio position as of Q1 2026 after selling out during the quarter.
  • Silverarc Capital Management sold 26,697 Gossamer Bio shares in Q1 2026, an estimated $6.62M.
  • Silverarc Capital Management first reported a position in Gossamer Bio in Q4 2022 and held it in 11 quarters.
  • Silverarc Capital Management's Gossamer Bio position peaked at $12.6M in Q3 2025.
  • 181 funds tracked by Wall St. Rank held Gossamer Bio as of Q1 2026.

Based on Silverarc Capital Management's 13F filing for Q1 2026, filed 14 May 2026.